soul trial semaglutide Presented at #ACC25: Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral (14 mg) was associated with a lower risk of cardiovascular events than placebo SOUL (Semaglutide cardiOvascular oUtcomes triaL)
Pay in 4 interest-free payments of $7.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3






/https%3A%2F%2Fopengraph.b-cdn.net%2Fproduction%2Fimages%2F2ed46913-f157-43c3-9418-19fea49af16c.png%3Ftoken%3DUl4O1QAtXTaMUjOfpBooUL-C8jajM-YwYFPrjCtr6ms%26height%3D1080%26width%3D1080%26expires%3D33315971423/og.png)





















